Hugel’s nine-month sales rise 15% on strong Korea, Europe demand

By Maekyung News Service

South Korean biopharmaceutical company Hugel reported a 15 percent increase in revenue for the first nine months of 2026, driven by stronger sales of botulinum toxin products, dermal fillers and skin boosters in its domestic and European markets.

Cumulative revenue reached 352.1 billion won ($262.5 million) in the January-September period, the company said on Wednesday.

For the third quarter, Hugel posted consolidated revenue of 97.5 billion won, operating profit of 18.1 billion won and net profit of 4.7 billion won.

Botulinum toxin sales fell 21 percent from a year earlier to 47.2 billion won, while revenue from fillers and skin boosters rose 2 percent to 30.9 billion won. Sales of cosmetics and other products increased more than 25 percent to 19.4 billion won.

South Korea was a major growth driver, with combined domestic sales of botulinum toxins, fillers and skin boosters jumping 54 percent to 27.4 billion won. The company said domestic sales of these products have increased every quarter since the third quarter of 2025.

Combined sales of the three product categories in Europe and other markets rose 18 percent to 17.8 billion won.

Hugel said it ranked second in China’s botulinum toxin market with a 22 percent share. In Brazil, the company recorded its highest quarterly sales since reentering the market a year earlier.

Performance in the United States was temporarily affected by a restructuring of Hugel’s distribution partnership into a contract sales organization model.

The company expects the new arrangement to give it greater control over U.S. sales operations and strengthen the commercial presence of its botulinum toxin brand, Letybo.

“We have made significant progress in establishing a direct commercial operating model in the United States, one of our key markets,” said Carrie Strom, Hugel’s global chief executive officer. She said the company would leverage Letybo’s competitiveness to strengthen its medium- to long-term profitability.

Hugel Korea CEO Daniel Chang said strong domestic performance in both toxins and fillers reaffirmed the company’s growth potential.

He added that Hugel would continue strengthening its core businesses while diversifying its product portfolio.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.